In a Phase 2b clinical trial, oral povorcitinib showed promise at week 52 for treating extensive nonsegmental vitiligo.

Published Date: 27 Oct 2023

USA: Significant total body and facial vitiligo was linked to oral povorcitinib treatment in adult patients with extensive nonsegmental vitiligo.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More Americans Are Surviving Cancer. But the Mental Health Challenges Can Persist.

2.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

3.

We Don't Always Know What's 'Best' for Our Patients

4.

Should the UK introduce targeted prostate cancer screening? The case for and against

5.

Germline Profiling May Improve Risk Stratification in t-MNs


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot